Results 41 to 50 of about 993 (163)

The Importance of Early Mycological Clearance of Uncomplicated Candidaemia and Its Implications for Clinical Practice. [PDF]

Mycoses
ABSTRACT Invasive candidiasis is a life‐threatening infection associated with high morbidity, mortality and healthcare costs in both general and critical care settings. Timely diagnosis and adequate antifungal treatment are essential to improving patient outcomes and limiting unnecessary use of healthcare resources.
Cornely OA, Bassetti M, Garcia-Vidal C, Hoenigl M, Maertens J, Martin-Loeches I, Mira JP, White PL.   +7 more
europepmc   +2 more sources

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin [PDF]

Open Forum Infectious Diseases, 2021
Abstract Background Rezafungin (RZF) is a novel echinocandin antifungal being developed for treatment of candidemia and invasive candidiasis, and for prevention of invasive fungal diseases among immunosuppressed patients.
Huguet, Jade, Ong, Voon, Sandison, Taylor, Melara, Rebeca M, Marbury, Thomas C, Jandourek, Alena, Flanagan, Shawn   +6 more
openaire   +1 more source

Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections

Antimicrobial Agents and Chemotherapy, 2021
Rezafungin is a novel antifungal agent of the echinocandin class with potent activity against species ofCandidaandAspergillus, including subsets of resistant strains, andPneumocystis jirovecii. The objective of this analysis was to develop a population pharmacokinetic (PK) model to characterize the disposition of rezafungin in plasma following ...
Christopher M. Rubino, Shawn Flanagan
openaire   +2 more sources

Rezafungin: an opportunity to personalize the treatment of patients with candidemia. [PDF]

Crit Care
Honore PM, Cornely OA, Soriano A.
europepmc   +3 more sources

infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin [PDF]

, 2023
Introduction: Invasive Candida Infections (ICIs) have undergone a series of significant epidemiological, pathophysiological, and clinical changes during the last decades, with a shift toward non-albicans species, an increase in the rate of exogenous ...
Federico Pea, De Rosa, Francesco Giuseppe, Carlo Tascini, Tascini, Carlo, Mario Venditti, Pea, Federico, Sanguinetti, Maurizio, Malgorzata Mikulska, Mikulska, Malgorzata, Maurizio Sanguinetti, Oliva, Alessandra, Venditti, Mario, Francesco Giuseppe De Rosa, Alessandra Oliva   +13 more
core   +3 more sources

Rezafungin Utilisation in Real Life-FungiScope Results From Europe and the United States. [PDF]

Mycoses
ABSTRACT Background Rezafungin, a novel echinocandin with once‐weekly intravenous dosing, offers potential advantages for outpatient parenteral antifungal therapy (OPAT) in invasive candidiasis (IC). While clinical trial data support its efficacy and safety, real‐world experience remains limited.
Reinhold I, Mori G, Lanzafame M, Limongelli A, Vena A, Götz J, Bauernfeind S, Hanses F, Tometten L, Mayer M, Rieke A, Soriano-Martin A, Valerio M, Vazquez JA, Yue P, Rahimli L, Azimli N, Sal E, Salmanton-García J, Vasenda N, Sprute R, Stemler J, Wingen-Heimann S, Cornely OA, Seidel D.   +24 more
europepmc   +2 more sources

Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species

Journal of Fungi, 2020
Rezafungin is a next-generation echinocandin that has favorable pharmacokinetic properties. We compared the occurrence of paradoxical growth (PG) and trailing effect (TE) characteristics to echinocadins with rezafungin, caspofungin, micafungin and ...
Zoltán Tóth, Lajos Forgács, Tamás Kardos, Renátó Kovács, Jeffrey B. Locke, Gábor Kardos, Fruzsina Nagy, Andrew M. Borman, Awid Adnan, László Majoros   +9 more
doaj   +1 more source

2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program

Open Forum Infectious Diseases, 2023
Abstract Background Rezafungin (RZF) is a new echinocandin (ECH) approved by the US FDA to treat candidemia and invasive candidiasis (IC). Fluconazole (FLC) resistance (R) is a raising concern to treat IC, and ECHs are often used as first-line therapy.
Carvalhaes, Cecilia G, Rhomberg, Paul, Klauer, Abby, Castanheira, Mariana   +3 more
openaire   +1 more source

Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum

Microorganisms, 2021
Candida auris is an emerging and frequently multidrug-resistant pathogen against which the echinocandins are the preferred therapeutic option. We compared killing activities of anidulafungin, caspofungin, micafungin, and rezafungin against 13 isolates ...
Renátó Kovács, Zoltán Tóth, Jeffrey B. Locke, Lajos Forgács, Gábor Kardos, Fruzsina Nagy, Andrew M. Borman, László Majoros   +7 more
doaj   +1 more source

Exploring Early Antifungal Activity of Rezafungin as a Stepping-Stone for Shorter Treatment Duration for Candidemia: Pooled Analysis of 2 Randomized Trials. [PDF]

Open Forum Infect Dis
BackgroundGuidelines recommend ≥2 weeks of antifungal therapy after candidemia clearance and for invasive candidiasis (IC). This post-hoc analysis evaluates Day 7 pooled data from the phase 2 STRIVE and phase 3 ReSTORE trials to explore early antifungal ...
Ostrosky-Zeichner L, Aram JA, Redell M, Thompson GR, Cornely OA, McKinnell JA, Spec A, Pappas PG.   +7 more
europepmc   +2 more sources